Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic Deletion of Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis.
Breynaert C, de Bruyn M, Arijs I, Cremer J, Martens E, Van Lommel L, Geboes K, De Hertogh G, Schuit F, Ferrante M, Vermeire S, Ceuppens J, Opdenakker G, Van Assche G. Breynaert C, et al. Among authors: de bruyn m, de hertogh g. J Crohns Colitis. 2016 Nov;10(11):1336-1350. doi: 10.1093/ecco-jcc/jjw101. Epub 2016 May 17. J Crohns Colitis. 2016. PMID: 27194531
Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
de Bruyn M, Arijs I, De Hertogh G, Ferrante M, Van Assche G, Rutgeerts P, Vermeire S, Opdenakker G. de Bruyn M, et al. Among authors: de hertogh g. J Crohns Colitis. 2015 Dec;9(12):1079-87. doi: 10.1093/ecco-jcc/jjv148. Epub 2015 Sep 7. J Crohns Colitis. 2015. PMID: 26351381 Clinical Trial.
Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease.
de Bruyn M, Machiels K, Vandooren J, Lemmens B, Van Lommel L, Breynaert C, Van der Goten J, Staelens D, Billiet T, De Hertogh G, Ferrante M, Van Assche G, Vermeire S, Opdenakker G, Schuit F, Rutgeerts P, Arijs I. de Bruyn M, et al. Among authors: de hertogh g. Inflamm Bowel Dis. 2014 Feb;20(2):339-52. doi: 10.1097/01.MIB.0000438430.15553.90. Inflamm Bowel Dis. 2014. PMID: 24378596 Clinical Trial.
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S. Billiet T, et al. Among authors: de bruyn m. J Crohns Colitis. 2015 Dec;9(12):1120-6. doi: 10.1093/ecco-jcc/jjv156. Epub 2015 Sep 7. J Crohns Colitis. 2015. PMID: 26351386
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S. Arijs I, et al. Among authors: de bruyn m, de hertogh g. Gut. 2018 Jan;67(1):43-52. doi: 10.1136/gutjnl-2016-312293. Epub 2016 Oct 7. Gut. 2018. PMID: 27802155 Clinical Trial.
195 results